A Tale Of Two Expectations: NDI Notification Estimate And Guidance
Regulatory Burden Notice Prompts Doubt While Hope Endures For Revised Draft
This article was originally published in The Tan Sheet
Executive Summary
FDA’s estimates for supplement manufacturers’ burden for submitting NDI notifications continue to miss the mark widely, say trade group executives. The agency would be more on target, they say, with a revised draft guidance on NDI notifications expected to reflect stakeholders’ suggestions.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
